Claims

1. A compound of formula (I):



(I)

wherein:

R^1 represents a group selected from:











each ring of which optionally contains a further heteroatom N,

Z represents an optional substituent halogen,

alk represents alkylene or alkenylene,

T represents S, O or NH;

R^2 represents hydrogen, $-C_{1-6}$alkyl, $-C_{1-3}$alkylCONR^{a}R^b, $-C_{1-3}$alkylCO$_2$C$_{1-4}$alkyl, $-CO_2C_{1-4}$alkyl or $-C_{1-3}$alkylCO$_2$H;

R^a and R^b independently represent hydrogen, -C_{1-6}alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by -C_{1-4}alkyl, and optionally the S heteroatom is substituted by O, i.e. represents $S(O)_n$;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C_{1-4}alkyl, -C_{2-4}alkenyl, -CN, -CF_3, -NR^aR^b, -C_{0-4}alkylOR^e, -$C(O)R^f$ and -$C(O)NR^aR^b$;

R^e represents hydrogen or -C_{1-6}alkyl;

R^f represents -C_{1-6}alkyl;

Y represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is substituted by a group – C_{1-2}alkylNR^cR^d.

R^c and R^d, together with the nitrogen atom to which they are bonded, form a 4-membered heterocyclic ring optionally substituted by halogen, OH or –OC_{1-6}alkyl, or a 5- or 6-membered non-aromatic heterocyclic ring substituted by OH, –OC_{1-6}alkyl or 1 to 2 halogens, with the proviso that the substituent is not attached to a ring carbon atom adjacent to a heteroatom;

and/or pharmaceutically acceptable derivative thereof.

2. A compound according to claim 1 wherein R^1 represents a group selected from:






each ring of which optionally contains a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH.
and/or pharmaceutically acceptable derivative thereof.

3. A compound according to claim 1 or claim 2 wherein R^2 represents hydrogen and/or pharmaceutically acceptable derivative thereof.

4. A compound according to any one of claims 1-3 wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}$alkyl or $-NR^aR^b$ and/or pharmaceutically acceptable derivative thereof.

5. A compound according to any one of claims 1-4 wherein Y represents a 5 or 6 membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is substituted by a group $-CH_2NR^cR^d$ and/or pharmaceutically acceptable derivative thereof.

6. A compound according to claim 1 selected from:
(1*E*)-*N*-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide;
N-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)ethanesulfonamide;
N-((3*S*)-1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-6-chloro-1-benzothiophene-2-sulfonamide.
(*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]ethenesulfonamide;
(1*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide;

6-Chloro-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-benzothiophene-2-sulfonamide;
6-Chloro-*N*-{1-[2-fluoro-4-(2-{[3-(methyloxy)-1-azetidinyl]methyl}-1*H*-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl}-1-benzothiophene-2-sulfonamide formate;
and/or pharmaceutically acceptable derivative thereof.

7. A compound according to any of claims 1-6 and/or pharmaceutically acceptable derivative thereof for use in therapy.

8. A pharmaceutical composition comprising a compound according to any of claims 1-6 and/or pharmaceutically acceptable derivative thereof together with at least one pharmaceutical carrier and/or excipient.

9. Use of a compound according to any of claims 1-6 and/or pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor.

10. A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of a compound according to any of claims 1-6 and/or pharmaceutically acceptable derivative thereof.

11. A process for preparing a compound of formula (I) which comprises:

(a) reacting a compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



(II)



(III)

OR:

(b) by reacting compounds of formula (I) where R^2 is hydrogen with compounds of formula (XI):

$$R^2—T \qquad (XI)$$

wherein R^2 is $-C_{1-6}$alkyl, $-C_{1-3}$alkylCONR^{a}R^b, $-C_{1-3}$alkylCO_2C_{1-4}alkyl, or $-CO_2C_{1-4}$alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.